In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Celgene buys Juno for $9bn

Executive Summary

Confirming rumors that began swirling a week prior, Celgene Corp. announced that it signed a definitive agreement to acquire the remaining 90.3% of cellular immunotherapies developer Juno Therapeutics Inc. that it didn’t already own for $87 per share or roughly $9bn. The share price represents an 80% premium to Juno’s trading average for the ten days prior to the January 17 media speculation.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Partial Acquisition
    • Payment Includes Cash

Related Companies